Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: A prospective randomised double-blind controlled trial

Heart

Volumn 93, Issue 9, 2007, Pages 1126-1133

  Dhadwal, Kay ^a   Al Ruzzeh, Sharif ^a   Athanasiou, Thanos ^b   Choudhury, Marina ^a   Tekkis, Paris ^b   Vuddamalay, Pynee ^a   Lysler, Haifa ^a   Amrani, Mohamed ^a   George, Shane ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC ASPECT; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE DRUG DOSE; STERNAL WOUND INFECTION; SURGICAL INFECTION;

ADULT; AGE FACTORS; AGED; ANTIBIOTIC PROPHYLAXIS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; DRUG COSTS; ENGLAND; FEMALE; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STERNUM; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 34548170708     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.103002     Document Type: Article

References (27)

1. Milton H. Mediastinal surgery. Lancet 1897;1:872.
2. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992;104:590-9.
3. Ridderstolpe L, Gill H, Granfeldt H. Superficial and deep sternal wound complications: incidence, risk factors, and mortality. Eur J Cardiothorac Surg 2001;20:1168-75.
4. Jonkers D, Elenbaas T, Terporten P, et al. Prevalence of 90-days postoperative wound infections after cardiac surgery. Eur J Cardiothorac Surg 2003;23:97-102.
5. Gummert JF, Barten MJ, Hans C. Mediastinitis and cardiac surgery - an updated risk factor analysis in 10,373 consecutive adult patients. Thorac Cardiovasc Surg 2002;50:87-91.
6. Antunes PE, Prieto D, Ferrao de Oliveira J, et al. Renal dysfunction after myocardial revascularization. Eur J Cardiothorac Surg 2004;25:597-604.
7. Jarvis WR. Benchmarking for prevention: the Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance (NNIS) system experience. Infection 2003;31(Suppl 2):44-8.
8. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
9. Sharma M, Berriel-Cass D, Baran J Jr. Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol 2004;25:468-71.
10. Roy MC, Herwaldt LA, Embrey R, et al. Does the Centers for Disease Control's NNIS system risk index stratify patients undergoing cardiothoracic operations by their risk of surgical-site infection? Infect Control Hosp Epidemiol 2000;21:186-90.
11. Surgical site infection surveillance in England. CDR Weekly 2004;14:1-5.
12. McConkey SJ, L'Ecuyer PB, Murphy DM, et al. Results of a comprehensive infection control program for reducing surgical-site infections in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1999;20:533-8.
13. Maher KO, VanDerElzen K, Bove EL, et al. A retrospective review of three antibiotic prophylaxis regimens for pediatric cardiac surgical patients. Ann Thorac Surg 2002;74:1195-200.
14. Spelman D, Harrington G, Russo P, et al. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 2002;23:402-4.
15. Spiegelhalter DJ, Aylin P, Best NG, et al. Commissioned analysis of surgical performance using routine data: lessons from the Bristol inquiry. J R Stat Soc A 2002;165:191-221.
16. Rasbash J, Browne W, Goldstein H. A users guide to MLwiN. London: University of London, 2001.
17. Harrington G, Russo P, Spelman D, et al. Surgical-site infection rates and risk factor analysis in coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 2004;25:472-6.
18. Swenne CL, Lindholm C, Borowiec J, et al. Surgical-site infections within 60 days of coronary artery by-pass graft surgery. J Hosp Infect 2004;57:14-24.
19. Copeland M, Senkowski C, Ulcickas M, et al. Breast size as a risk factor for sternal wound complications following cardiac surgery. Arch Surg 1994;129:757-9.
20. Jakob HG, Borneff-Lipp M, Bach A, et al. The endogenous pathway is a major route for deep sternal wound infection. Eur J Cardiothorac Surg 2000;17:154-60.
21. Gardlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery - microbiology and pathogenesis. Eur J Cardiothorac Surg 2002;21:825-30.
22. Farber BF, Karchmer AW, Buckley MJ, et al. Vancomycin prophylaxis in cardiac operations: determination of an optimal dosage regimen. J Thorac Cardiovasc Surg 1983;85:933-5.
23. Maki DG, Bohn MJ, Stolz SM, et al. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg 1992;104:1423-34.
24. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus Cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of metlnicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002;123:326-32.
25. Salminen US, Viljanen TU, Valtonen W, et al. Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. J Antimicrob Chemother 1999;44:287-90.
26. Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998;19:234-9.
27. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706-15.